title: New anticoagulation drugs for atrial fibrillation.
abstract: Atrial fibrillation (AF) confers an increased risk of ischemic stroke or thromboembolism that is reduced by long-term oral anticoagulant therapy. Until recently, the latter has typically been one from the vitamin K antagonist (VKA) class of drugs. Although highly effective, VKAs have limitations, and their use is challenging for both patients and clinicians. A new generation of oral anticoagulant drugs is emerging, including several drugs that appear to be viable alternatives to VKAs in AF patients.
authors.affiliation: Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
authors.forename: T S
authors.initials: TS
authors.lastname: Potpara
authors.forename: G Y H
authors.initials: GY
authors.lastname: Lip
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage* / Q000097:blood; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D002986:Clinical Trials as Topic / Q000639:trends; D006801:Humans; D014812:Vitamin K / Q000037:antagonists & inhibitors* / Q000097:blood
chemical_list: D000925:Anticoagulants; D014812:Vitamin K